drugset
drugset / Trial / NCT00391586

Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung

NCT00391586 ↗

Phase 2 Terminated 45 enrolled New Mexico Cancer Research Alliance Genentech, Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

This study was conducted to compare the activities of erlotinib to that of intravenous, platinum-based therapy in the treatment of non-small cell lung cancer (NSCLC). The goal of this trial was to demonstrate clinical equivalence of erlotinib to platinum-based frontline therapy, compared to historical controls.

Timeline

Start
2006-07
Primary completion
2011-05
Completion
2012-05

Outcome

Outcome not reported

Stopped: “PI left institution.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Docetaxel Small molecule 35 mg/m2 Intravenous
Subject Docetaxel Small molecule 75 mg/m2 Intravenous
Subject Erlotinib Small molecule 150 mg Oral
Subject Etoposide Small molecule 100 mg/m2 Intravenous
Subject Etoposide Small molecule 200 mg/m2 Intravenous
Subject Gemcitabine Small molecule 1000 mg/m2 Intravenous
Subject Gemcitabine Small molecule 1250 mg/m2 Intravenous
Subject Irinotecan Small molecule 50 mg/m2 Intravenous
Subject Paclitaxel Small molecule 80 mg/m2 Intravenous
Subject Paclitaxel Small molecule 100 mg/m2 Intravenous
Subject Paclitaxel Small molecule 200 mg/m2 Intravenous
Subject Paclitaxel Small molecule 225 mg/m2 Intravenous
Subject Pemetrexed Small molecule 500 mg/m2 Intravenous
Subject Vinorelbine Small molecule 25 mg/m2 Intravenous

Indications

non-small cell lung carcinoma